SEC Comment Letter 0000000000-24-001013 to Silo Pharma, Inc. (SILO)
Silo Pharma, Inc.
Date: Jan. 25, 2024 · CIK: 0001514183 · Accession: 0000000000-24-001013
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276658
Letter
United States securities and exchange commission logo January 25, 2024 Eric Weisblum Chief Executive Officer Silo Pharma, Inc. 677 N. Washington Blvd. Sarasota, Florida 34236 Re:Silo Pharma, Inc. Registration Statement on Form S-3 Filed on January 23, 2024 File No. 333-276658 Dear Eric Weisblum: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Bradley Ecker at 202-551-4985 with any questions. Sincerely, Division of Corporation Finance Office of Manufacturing
Show Raw Text
United States securities and exchange commission logo
January 25, 2024
Eric Weisblum
Chief Executive Officer
Silo Pharma, Inc.
677 N. Washington Blvd.
Sarasota, Florida 34236
Re:Silo Pharma, Inc.
Registration Statement on Form S-3
Filed on January 23, 2024
File No. 333-276658
Dear Eric Weisblum:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Bradley Ecker at 202-551-4985 with any questions.
Sincerely,
Division of Corporation Finance
Office of Manufacturing